Jason Lindow

Jason is driven to execute clinical programs in his 25 years of experience spanning multiple indications with a focus on hematology and oncology. He planned, initiated, and managed dozens of complex, first-in-human and late staged oncology programs. He has a track record of accelerating timelines while maintaining good clinical practice. His experience in large and small biotechnology companies, as well as CROs, formed a wide foundation of clinical development experience.

Jason started his career at ALZA Corporation studying the effects of hormone replacement therapy in AIDS patients. He went on to work at Parexel and Clinimetrics conducting trials in HIV, renal cell carcinoma, and pain management. His focus in oncology started during his time at Genentech where he executed humanized monoclonal antibody treatments for various cancers. At Gilead, he drove the burgeoning oncology pipeline with a focus on first-in-human solid tumor drug development, and at AbbVie, he executed over 20 first-in-human trials with immunology-oncology products both as single agent and in novel-novel combinations to clinical proof of concept.

Since joining RevMed in 2021, Jason leads the growing Clinical Operations department. He graduated from UC San Diego and has held positions of increasing responsibility throughout his career.